Bradford C. Sippy
Chairman and Chief Executive Officer
+ Full Bio
Mr. Sippy founded Tremeau Pharmaceuticals in July 2016. He brings over 20 years of pharmaceutical industry experience across multiple therapeutic areas. He most recently served as Vice President and Head of U.S. Marketing for Sunovion Pharmaceuticals, where he oversaw all in-line, late stage, and new product planning activities for Sunovion’s entire US portfolio, including P&L responsibility for the blockbuster drugs LATUDA and LUNESTA. Previously to this he established and served as the head of Sunovion’s Neurology Business Unit, overseeing all commercial activities for the launch of the antiepileptic APTIOM for its initial and follow-on indications. Prior to joining Sunovion he held various roles of increasing responsibility in manufacturing, managed markets, sales, market research, and marketing at Merck Inc. and Roche Pharmaceuticals.
Among his commercial achievements, Mr. Sippy was named a Top 25 U.S. Marketer in 2012 by Parade Magazine and won the 2013 MM&M Gold Award for Best Multi-Channel Campaign, both in recognition for the creation of FOLLOW THE WINGS, the first and only PhRMA Code compliant reminder ad.
Prior to starting in the pharmaceutical industry Mr. Sippy worked for DuPont, where he pioneered a process that reduced the hazardous waste emissions of DuPont's largest site by >70%. For his contributions to the environment, Mr. Sippy was recognized by Edgar J. Woolard, CEO DuPont, with the 1994 Environment Excellence Award.
Mr. Sippy holds a bachelors of science with honors in Chemical Engineering from Purdue University and an MBA, cum laude, from the Stern School of Business at New York University. He is also a licensed patent agent and admitted to practice before the US Patent and Trademark office.
Mark Corrigan MD
Co-Founder and President of Research and Development
+ Full Bio
Dr. Corrigan Co-Founded Tremeau in 2016. From 2010 to 2014, he served as a Director, President and Chief Executive Officer of the public company, Zalicus Inc. prior to their merger with Epirus Biopharmaceuticals in July 2014. Dr. Corrigan also serves on the Boards of Cardiome, CoLucid, Nabriva, Quartet Medicine and is Chairman of the Board of BlackThorn Therapeutics.
Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) and served as their executive vice president of research and development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine where he oversaw the development and registration of Celebrex among other medicines.
Before Dr. Corrigan entered the pharmaceutical industry, he spent five years in academic research at the University of North Carolina, School of Medicine and maintains a faculty appointment as Adj. Prof. in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association.
Dr. Corrigan had served on the board of directors of Cubist Pharmaceuticals where he chaired the Scientific Committee and of Avanir Pharmaceuticals, Inc. where he also served as their chair of the SAC. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
Stewart H. Mueller
Consulting Head of Regulatory Affairs and Quality Assurance
+ Full Bio
Mr. Mueller joined Tremeau in 2016 as the Consulting Head of Regulatory Affairs and Quality Assurance. Mr. Mueller is the Principal of SHM Pharma Consulting LLC and he brings more than 35 years of biopharmaceutical experience to guide Tremeau’s regulatory strategy and quality systems development. Mr. Mueller obtained more than 10 U.S. NDA and BLA approvals and over 175 global approvals in a variety of therapeutic areas and geographies.
Prior to joining Tremeau, Mr. Mueller spent 18 years with Sunovion Pharmaceuticals (Formerly Sepracor) as the Senior Vice President, Regulatory Affairs and Quality Assurance, responsible for establishing and managing both the RA and QA functions. Mr. Mueller also recently served as the Head of Global Quality Assurance for Sumitomo Dainippon Pharmaceuticals (Sunovion's parent company), responsible for the global quality and compliance system for the parent company and its affiliates.
Prior to his time at Sunovion/Sumitomo, Mr. Mueller held several roles of increasing responsibility in regulatory affairs and quality assurance with Rhone-Poulenc Rorer, responsible for small molecule projects, biologics, plasma-derivative products, and gene and cell therapy programs. Before Mr. Mueller joined the pharmaceutical industry, he spent 7 years working for the Food and Drug Administration and served as a Supervisory Investigator in the New York District Office.
Mr. Mueller holds an MBA in technology management from UOP, an MS in pharmaceutics from Temple University and a BS in geophysics from CCNY.